---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-014392"
form_type: "8-K"
ticker: "ALT"
cik: "0001326190"
company_name: "Altimmune, Inc."
filed_at: "2022-09-14T23:59:59+00:00"
generated_at: "2026-06-23T09:39:05.900998+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Altimmune Phase 1b pemvidutide: 68.5% liver fat reduction, 4.9% weight loss at 12 weeks

## Summary
- At 1.8 mg dose, relative liver fat reduction of 68.5%; 94.4% of subjects achieved ≥30% reduction.
- Mean weight loss of 4.9% in non-diabetic subjects (placebo-adjusted 4.7%) at 1.8 mg dose.
- 55.6% of subjects at 1.8 mg achieved liver fat normalization (≤5%).
- No serious or severe adverse events; 2 discontinuations due to GI intolerance.
- Serum ALT declined >17 IU/L in subjects with baseline ALT ≥30 IU/L; no clinically significant ALT elevations.

## SEC filing metadata
- accession: 0001558370-22-014392
- form_type: 8-K
- ticker: ALT
- cik: 0001326190
- company_name: Altimmune, Inc.
- filed_at: 2022-09-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326190/000155837022014392/0001558370-22-014392-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326190/000155837022014392/alt-20220914x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-014392
- JSON: https://secwatch.observer/filing/0001558370-22-014392.json
- Plain text: https://secwatch.observer/filing/0001558370-22-014392.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.